# Retatrutide: Research Overview — Peptide Batteries > A data-forward literature summary of retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist. Mechanism, Phase 2 trial numbers, and cited safety cautions, none of it approved-label data. An investigational triple agonist that adds glucagon-receptor activation to the GIP/GLP-1 combination — the only compound on this site engineered specifically to raise energy expenditure, not just cut appetite. ## The short version Retatrutide (lab code LY3437943) is an experimental peptide drug still in Phase 3 trials — it is not approved by the FDA or any other regulator, anywhere, as of mid-2026. What makes it relevant to a cellular-energy frame is its third receptor target: most weight-loss peptides work by reducing food intake, but retatrutide also activates the glucagon receptor, a target specifically linked to raising how much energy the body burns. In its Phase 2 obesity trial, participants on the highest dose lost an average of 24.2% of body weight over 48 weeks, against 2.1% for placebo [16]. This page reports the trial numbers, the mechanism behind the third receptor arm, and the safety signals the trials have flagged so far — heart rate, GI tolerability, lean mass — with no dose recommended and no claim that its investigational data predicts an eventual approved label. ## What it is Retatrutide is a synthetic, 39-amino-acid peptide built on a GIP-hormone backbone, with a C20 fatty-diacid chain attached to bind albumin and extend its half-life — the standard engineering trick behind once-weekly injectable peptide drugs. Its molecular formula (free acid) is C221H342N46O68. It is classified as a triple agonist: a single molecule engineered to activate three separate receptors — GIP, GLP-1, and the glucagon receptor — at once, rather than the one or two receptors most incretin-class drugs target. Cryo-EM structural work resolved exactly how it does this: retatrutide is roughly 8.9 times more potent at the GIP receptor than native GIP hormone itself, but only 0.3 and 0.4 times as potent at the glucagon and GLP-1 receptors compared with their native hormones — a deliberately imbalanced, not equal, three-way engagement [14]. ## How it works Retatrutide's GLP-1 and GIP receptor arms work the way single- and dual-agonist drugs already do: they suppress appetite and improve glucose-dependent insulin secretion, the same mechanism underlying tirzepatide's effects. The addition that defines retatrutide is the third arm — controlled activation of the glucagon receptor. Glucagon is usually thought of as insulin's opposite number, the hormone that tells the liver to release stored glucose, but at the calibrated level retatrutide engages it, the proposed effect is different: increased energy expenditure and lipid mobilization, rather than a meaningful rise in blood glucose. The mechanism is meant to work on both sides of the energy-balance equation simultaneously — reduced intake from the GLP-1/GIP arms, increased expenditure from the glucagon arm — which is the mechanistic argument for why retatrutide has, in trials to date, produced larger weight loss than dual- or single-agonist therapy [13][14]. ## What the research shows A 2025 narrative review synthesizes retatrutide's Phase 1/2 pharmacology and frames the up-to-24% weight-loss figure as a step-change versus prior incretin therapies, while also describing the GI and heart-rate safety profile and the status of the ongoing Phase 3 TRIUMPH program [13]. The 2024 cryo-EM paper described above resolved the three receptor-binding structures at 2.68, 3.26, and 2.84 Å and confirmed the imbalanced potency profile via cAMP signaling assays and alanine-mutant experiments [14]. The clinical numbers are the core of the evidence base. In a 48-week Phase 2 trial of 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean -24.2% body-weight change versus -2.1% with placebo; GI adverse events were dose-related and mostly mild-to-moderate, and a dose-dependent heart-rate increase peaked around 24 weeks [16]. A 36-week Phase 2 trial in 281 adults with type 2 diabetes found the same 12 mg dose lowered HbA1c by -2.02 percentage points at 24 weeks and cut body weight by 16.94% at 36 weeks, versus -0.01% and -3.00% for placebo respectively, with no severe hypoglycemia and no deaths [17]. A dedicated 48-week substudy in 98 participants with obesity and metabolic dysfunction-associated steatotic liver disease found retatrutide 12 mg cut relative liver fat by -82.4% at 24 weeks, with 86% of participants reaching normal liver fat (under 5%), a reduction sustained to -86.0% at 48 weeks [15]. ## Reported effects, cautions & safety Community reports about retatrutide come from research-use forums, not from an approved medicine's monitored patient population — anecdotal, not clinical evidence, and none of it tied to a confirmed dose. The most consistently described effect is a near-total quieting of 'food noise,' the intrusive mental loop of thinking about eating, alongside weight loss that community members describe as faster than what they recall from other incretin-class compounds — broadly consistent with, though not proof of, the trial-level -24.2% figure above. A subset reports a distinct warmth or mild thermogenic sensation, which community discussion attributes to the glucagon-receptor arm's effect on energy expenditure. On the adverse side, nausea peaking four to eight hours post-injection is the most frequent complaint, especially early on or after a dose increase; noticing a faster resting heart rate on a wearable device — sometimes 5-15 bpm above baseline — is a recurring theme that maps to the dose-dependent heart-rate signal documented in trials; sulfur burps, constipation, and early fatigue are also commonly mentioned. The cited safety literature is more pointed. Retatrutide is unapproved and investigational, and material obtained outside a clinical trial has no verified identity, purity, or sterility — independent analyses of similar gray-market peptides have found truncated sequences and misidentified compounds, and the FDA issued more than 50 warning letters to retatrutide vendors in 2025 [16][13]. Dose-dependent GI adverse events were the leading cause of trial discontinuation, affecting up to 45% of participants at the highest dose [16]. The dose-dependent heart-rate increase, roughly 5-7 bpm at the highest doses, is being followed in a dedicated, still-unreported cardiovascular outcomes trial [16]. Combined with insulin or a sulfonylurea, retatrutide's insulin-secretion effect can raise hypoglycemia risk without clinical monitoring to catch it [17]. Long-term safety, and whether the Phase 2 signal holds in Phase 3, remain open questions. ## Where it fits in cellular energy and metabolism Retatrutide is the only compound on this site explicitly engineered to raise energy expenditure rather than simply cut intake — the glucagon-receptor arm is a direct energy-metabolism lever, a cleaner fit for this frame than its investigational, unapproved status might suggest. Next to [tirzepatide](/tirzepatide), it represents a further step along the same receptor-engagement ladder: two arms versus three, with retatrutide's Phase 2 weight-loss figure exceeding tirzepatide's approved-label results so far, though without Phase 3 confirmation [16]. It shares [MOTS-c](/mots-c)'s AMPK-adjacent metabolic territory only loosely — retatrutide works through cell-surface hormone receptors, not a mitochondrial-encoded intracellular signal. Compare all four compounds directly on the [comparison page](/compare). --- A data-forward digest of peptide research — effect sizes and study designs, reported as measured, never as a prescription.